Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

55.13 -1.37 (-2.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 904,189
Open 56.33
Bid (Size) 52.00 (1)
Ask (Size) 59.00 (1)
Prev. Close 56.50
Today's Range 54.21 - 57.33
52wk Range 29.16 - 57.65
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Cash-Producing Stocks That Fall Short
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Emerges as a Top Affordable Growth Candidate
Supernus Pharmaceuticals (SUPN) offers affordable growth with strong EPS, solid financials, and a low P/E ratio, making it a compelling investment opportunity. 
Via Chartmill

Performance

YTD
+51.3%
+51.3%
1 Month
+15.4%
+15.4%
3 Month
+57.1%
+57.1%
6 Month
+69.9%
+69.9%
1 Year
+58.1%
+58.1%

More News

Read More
Deep Dive Into Supernus Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
3 Small-Cap Stocks We’re Skeptical Of
Via StockStory
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
3 Stocks Under $50 We Steer Clear Of
Via StockStory
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Presents a Compelling Mix of Growth and Technical Momentum
Via Chartmill
Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines
Via StockStory
Topics Artificial Intelligence Intellectual Property
Supernus Pharmaceuticals (SUPN) Stock Is Up, What You Need To Know
Via StockStory
Topics Artificial Intelligence
Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Q2 Earnings Highs And Lows: Organon (NYSE:OGN) Vs The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Represents an Affordable Growth Opportunity
Via Chartmill
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
Via Benzinga
Topics ETFs
Branded Pharmaceuticals Stocks Q2 Highlights: Collegium Pharmaceutical (NASDAQ:COLL)
Via StockStory
Topics Artificial Intelligence Intellectual Property
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
From Biogen Inc.
Via GlobeNewswire
3 Overrated Stocks with Questionable Fundamentals
Via StockStory
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Emerges as a Top Affordable Growth Stock
Via Chartmill
Unpacking Q2 Earnings: Eli Lilly (NYSE:LLY) In The Context Of Other Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
1 Cash-Producing Stock to Research Further and 2 We Brush Off
Via StockStory
Unpacking Q2 Earnings: Elanco (NYSE:ELAN) In The Context Of Other Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
2 Healthcare Stocks on Our Watchlist and 1 We Avoid
Via StockStory
Topics Stocks
Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q2
Via StockStory
Topics Artificial Intelligence Intellectual Property
Supernus Pharmaceuticals to Participate in September Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY)
Via StockStory
Topics Artificial Intelligence Intellectual Property
1 Unpopular Stock That Deserves a Second Chance and 2 Facing Headwinds
Via StockStory

Frequently Asked Questions

Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?
Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market
What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 55.13
When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 10/31/25 04:00 PM ET
What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 2.93B
How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
Supernus Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.